Lung Non-Small Cell Carcinoma with KRAS Mutation

Lung Non-Small Cell Carcinoma with KRAS Mutation — Trials · CancerIndex

Clinical trials

Registered studies

1 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 0
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: —
Top sponsor: —
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–1 of 1 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02258607	Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase	terminated	Phase 1	21	Sierra Oncology LLC - a GSK companyINDUSTRY	1	Feb 1, 2019	clinicaltrials

Data updated 22 days agoSource updated Feb 1, 2019source: clinicaltrials